Pharmacotherapy for anxiety disorders and comorbid alcohol dependency

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2008, Pages

  Wilson, Don ^a   Ipser, Jonathan C ^b   Stein, Dan J ^c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE; LORAZEPAM; MIRTAZAPINE; NALTREXONE; PLACEBO; PREGABALIN;

ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY DISORDER; COGNITIVE THERAPY; COMORBIDITY; DETOXIFICATION; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 55049139618     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007505     Document Type: Review

References (57)

1. Alonso 2004 Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC, Kovess V, Lépine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J, Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M, Domingo-Salvany A, Ferrer M, Joo SS, Martínez-Alonso M, Matschinger H, Mazzi F, Morgan Z, Morosini P, Palacín C, Romera B, Taub N, Vollebergh WA, ESEMeD/MHEDEA 2000 Investigators, European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. 12-month comorbidity patterns and associated factors in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) Project. Acta Psychiatr Scand Suppl 2004;420:28-37.
2. Als-Nielsen 2003 Als-Nielsen B, Chen W, Gluud C, Kjaergard LL. Association of funding and conclusions in randomized drug trials - A reflection of treatment effect or adverse events?. Journal of the American Medical Association 2003;290:921-928.
3. APA 1980 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-III). 3rd Edition. Washington, DC: American Psychiatric Association, 1980.
4. APA 1994 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington, DC: American Psychiatric Association, 1994.
5. APA 2000 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR). 4th Edition. Washington, DC: American Psychiatric Association, 2000.
6. Back 2006 Back SE, Brady KT, Sonne SC, Verduin ML. Symptom improvement in co-occurring PTSD and alcohol dependence. Journal of Nervous and Mental Disease 2006;194(9):690-6.
7. Baker 2003 Baker CB, Johnsrud MT, Crismon ML ROBERT A. ROSENHECK, SCOTT W. WOODS. Quantitative analysis of sponsorship bias in economic studies of antidepressants. British Journal of Psychiatry 2003;183:498-506.
8. BAP 2005 Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU, British Association for Psychopharmacology. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19(6):567-96.
9. Beck 1961 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961;4:561-571.
10. Bills 1993 Bills LJ, Kreisler K. Treatment of flashbacks with naltrexone. American Journal of Psychiatry 1993;150(9):1430.
11. Blake 1990 Blake DD, Weathers FW, Nagy LM, et al.A clinician rating scale for assessing current and lifetime PTSD: The CAPS-1. Behavior Therapy 1990;21:187-8.
12. Bowen 2000 Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial of cognitive behavioral treatment of panic in alcoholic inpatients with comorbid panic disorder. Addictive Behaviors 2000;25(4):593-7.
13. Brady 1993 Brady KT, Lydiard RB. The association of alcoholism and anxiety. Psychiatr Q 1993;64(2):135-49.
14. CPA 2006 Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders. Canadian Journal of Psychiatry 2006;51(8 Suppl 2):9S-91S.
15. Deeks 2001 Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis.. In: Egger M, Davey SG, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. BMJ Publication Group, 2001.
16. Deeks 2002 Deeks JJ. Issues in the selection of a summary statistic for meta-analysis of clinical trials with binary outcomes. Statistics in Medicine 2002;21(11):1575-600.
17. Deeks 2005 Deeks J, Higgins J, Altman D. Cochrane Reviewers Handbook 4.2.5 [updated May 2005]. In: Alderson P, Green S, Higgins J editor(s). The Cochrane Library. Chichester, UK: John Wiley & Sons, Ltd., 2005.
18. Dickersin 1992 Dickersin K, Min YI, Meinert CL. Factors influencing the publication of research results : follow-up of applications submitted to two substantial review boards. JAMA 1992;267(3):374- 8.
19. Driessen 2001 Driessen M, Meier S, Hill A, Wetterling T, Lange W, Junghanns K. The course of anxiety, depression and drinking behaviours after completed detoxification in alcoholics with and without comorbid anxiety and depressive disorders. Alcohol & Alcoholics 2001;36(3):249-55.
20. Elbourne 2002 Elbourne DR, Altman DG, Higgins JPT, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: Methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
21. Feltner 2003 Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. A randomized, double-blind, placebo-controlled, fixed-dose, multi-center study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 2003;23(3):240-249.
22. Guy 1976 Guy W. ECDEU assessment manual for psychopharmacology. Washington, DC: U.S. National Institute of Health, 1976.
23. Hamilton 1959 Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32:50-5.
24. Hashin 2007 Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry 2007;64(7):830-42.
25. Higgins 2003 Higgins JTP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(6):557-60.
26. Kendall 2004 Kendall PC, Safford S, Flannery-Schroeder E, Webb A. Child anxiety treatment: outcomes in adolescence and impact on substance use and depression at 7.4-year follow-up. Journal of Consulting and Clinical Psychology 2004;72(2):276-87.
27. Kessler 1996 Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ. The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. American Journal of Orthopsychiatry 1996;66(1):17-31.
28. Kessler 1997 Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Archives of General Psychiatry 1997;54(4):313-21.
29. Khantzian 1985 Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. American Journal of Psychiatry 1985;142(11):1259-64.
30. Kranzler 1996 Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcoholism: Clinical and Experimental Research 1996;20(9):1534-41.
31. Krystal 2006 Krystal JH, Staley J, Mason G, Petrakis IL, Kaufman J, Harris RA, Gelernter J, Lappalainen J. Gamma-aminobutyric acid type A receptors and alcoholism: intoxication, dependence, vulnerability, and treatment. Archives of General Psychiatry 2006;63(9):957-68.
32. Kushner 1990 Kushner MG, Sher KJ, Beitman BD. The relation between alcohol problems and the anxiety disorders. American Journal of Psychiatry 1990;147(6):685-95.
33. Kushner 2005 Kushner MG, Abrams K, Thuras P, Hanson KL, Brekke M, Sletten S. Follow-up study of anxiety disorder and alcohol dependence in comorbid alcoholism treatment patients. Alcoholism: Clinical and Experimental Research 2005;29(8):1432-43.
34. Liappas 2003 Liappas J, Paparrigopoulos T, Tzavellas E, Christodoulou G. Alcohol detoxification and social anxiety symptoms: a preliminary study of the impact of mirtazapine administration. Journal of Affective Disorders 2003;76(1-3):279-84.
35. Liebowitz 1987 Liebowitz MR. Social Phobia. Modern Problems in Pharmacopsychiatry 1987;22:141-173.
36. Lubin 2002 Lubin G, Weizman A, Shmushkevitz M, Valevski A. Short-term treatment of post-traumatic stress disorder with naltrexone: an open-label preliminary study. Human Psychopharmacology 2002;17(4):181-5.
37. Malcolm 2002 Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. Journal of General Internal Medicine 2002;17(5):349-55.
38. Montgomery 1979 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. British Journal of Psychiatry 1979;134:382-389.
39. Morris 2005 Morris EP, Stewart SH, Ham LS. The relationship between social anxiety disorder and alcohol use disorders: a critical review. Clinical Psychology Review 2005;25(6):734-60.
40. NICE 2005 NICE Clinical Guideline 31. Obsessive-Compulsive Disorder: Core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder.. www.nice.org.uk 2005.
41. Pande 2004 Pande AC, Feltner DE, Jefferson JW, Davidson JRT, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowoski M, DuBoff E, Phelps M, Janney CA, Werth JL. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. Journal of Clinical Psychopharmacology 2004;24(2):141-149.
42. Pettinati 2000 Pettinati HM, Volpicelli JR, Kranzler HR, Luck G, Rukstalis MR, Cnaan A. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcoholism: Clinical and Experimental Research 2000;24(7):1041-9.
43. Pohl 2005 Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. Journal of Clinical Psychopharmacology 2005;25(2):151-8.
44. Randall 2001 Randall CL, Thomas S, Thevos AK. Concurrent alcoholism and social anxiety disorder: a first step toward developing effective treatments. Alcoholism: Clinical and Experimental Research 2001;25(2):210-20.
45. Regier 1990 Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264(19):2511-8.
46. Rickels 2005 Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Archives of General Psychiatry 2005;62(9):1022-30.
47. Robinson 2002 Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. International Journal of Epidemiology 2002;31:150- 153.
48. Schade 2003 Schadé A, Marquenie LA, Van Balkom AJ, De Beurs E, Van Dyck R, Van Den Brink W. Do comorbid anxiety disorders in alcohol-dependent patients need specific treatment to prevent relapse?. Alcohol & Alcoholism 2003;38(3):255-62.
49. Schade 2005 Schadé A, Marquenie LA, van Balkom AJ, Koeter MW, de Beurs E, van den Brink W, van Dyck R. The effectiveness of anxiety treatment on alcohol-dependent patients with a comorbid phobic disorder: a randomized controlled trial. Alcoholism: Clinical and Experimental Research 2005;29(5):794-800.
50. Schuckit 1988 Schuckit MA, Monteiro MG. Alcoholism, anxiety and depression. British Journal of Addiction 1988;83(12):1373-80.
51. Sheehan 1996 Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. International Clinical Psychopharmacology 1996;11 Suppl 3:89-95.
52. Sobell 1992 Sobell LC, Sobell MB. Timeline Follow-Back: A technique for assessing self-reported ethanol consumption. In: Allen J, Litten RZ editor(s). Measuring Alcohol Consumption: Psychological and Biological Methods. Totowa: Humana Press, 1992:41-72.
53. Song 2000 Song F, Eastwood AJ, Gilbody S, Duley L, Sutton AJ. Publication and related biases. Health Technology Assessment 2000;4:1-115.
54. Spitzer 1996 Spitzer R, Williams J, Gibbons M. Instructional manual for the structured clinical interview for DSM-IV. New York: New York State Psychiatric Institute, 1996.
55. Verbeke 2000 Verbeke M, Molenberghs G. Linear Mixed Models for Longitudinal Data. New York: Springer, 2000.
56. Ware 1992 Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
57. Watkins 2005 Watkins KE, Hunter SB, Burnam MA, Pincus HA, Nicholson G. Review of treatment recommendations for persons with a co-occurring affective or anxiety and substance use disorder. Psychiatric Services 2005;56(8):913-26.